New radioligand therapy with 177Lu-PSMA-617 in men with metastatic prostate cancer: Initial clinical experience after 50 therapy cycles.

e16575Background: Despite several new treatment options in metastatic castration resistant prostate cancer (mPCa), especially in castration resistant PCa (mCRPC), eventual resistance to approved tr...